Glecaprevir

DB13879ApprovedInvestigationalSmall moleculeNS3/4A Protease Inhibitors

Glecaprevir is a Hepatitis C NS3/4A protease inhibitor used to treat Hepatitis C. In combination with DB13878, glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors.

Chemical structure of Glecaprevir
Mechanism
Curator reviewed · 3 references
Primary indication
Indicated for the treatment of adult patients with acute and chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).Curator reviewed · 27 structured indications
Formula / weight
C38H46F4N6O9S · 838.87 g/mol (avg)
First approval
Canada, 2017 · United States, 2017 · European Union, 2020
Code names
A-1282576 · A-1282576.0 · ABT-493
Brand names
  • Maviret
  • Mavyret

Resolves to

Structure
InChIKeyMLSQGNCUYAMAHD-ITNVBOSISA-NSMILES[H][C@@]12CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC\C=C\C(F)(F)C3=NC4=C(C=CC=C4)N=C3O1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
4TransportersSubstrate / inhibitor direction, not just membership
Listed above
551Drug interactionsStructured to mechanism, not free text
Sign in
47Clinical trialsPhase, status and sponsor resolved per trial
Sign in
27Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
11Marketed productsAcross 8 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 40 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Glecaprevir, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account